Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- MTPC Licenses Novel Pruritus Treatment from Toray in North America
October 17, 2011
- Otsuka Medical Devices to Acquire KiSCO Group Companies
October 17, 2011
- IBL Launches ANGPTL2 Assay Kit
October 17, 2011
- 60% Rule Likely to Replace 70% Rule for New Generics: Mr Kikuchi of Nichi-Iko MPI
October 17, 2011
- CMIC Forms a Chinese Joint Venture, Making Capital Investment in Local CRO
October 14, 2011
- Nichi-Iko to Be Delisted from OSE, NSE
October 14, 2011
- Nichi-Iko Revises Full-year Forecasts Downward Despite Double-digit Growth in Sales
October 14, 2011
- Daiichi Sankyo Resubmits NDA for Iron Deficiency Anemia Treatment Injectafer to FDA
October 14, 2011
- Shionogi Completes TOB for C&O Pharmaceutical Technology of China
October 14, 2011
- Nihon Chouzai Aims to Triple Home Healthcare, Nursing Facility Business in 2 Years
October 14, 2011
- Eli Lilly Japan Applies for Strattera for AD/HD in Adults
October 13, 2011
- Hisamitsu Posts 2.7% Loss in Mar-Aug Results on Shipping Adjustments of Main Products
October 13, 2011
- Doctor Survey for Information Provision Through Tablet Computers: Otsuka, Takeda Lead HP, GP
October 13, 2011
- Hisamitsu: Sales of Norspan Lower Than Expected
October 13, 2011
- CHMP Recommends Approval of Novo’s Levemir for Type I Diabetes in Children
October 13, 2011
- Asahi Kasei Pharma to Start Clinical Trials in 2012 of US Transdermal Patch Formulation
October 12, 2011
- NanoCarrier, France’s LFB Agree on Joint Research Agreement
October 12, 2011
- MediciNova Gets Approval for Chinese Joint Venture
October 12, 2011
- PIII Study of Rivaroxaban in Patients with ACS to be Presented at AHA Congress: Bayer
October 12, 2011
- Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…